Considering that laryngeal carcinomas have a high mutational burden due to frequent mutations in genes responsible for DNA repair, and in line with our results that demonstrate an increase in STING expression in the advanced stages of the disease, it is conceivable that laryngeal cancer is a good candidate for the use of PARP inhibitors and STING agonists in metastatic and non-metastatic advanced stages of the disease and in combination with standard therapy (radiotherapy, chemotherapy, chemoradiotherapy, and ICIs) in different timeline settings (primary, neoadjuvant, and adjuvant treatment). This evidence concerns the gene STING1 and laryngeal carcinoma.